Currently out of the existing stock ratings of Christopher Marai, 128 are a BUY (85.33%), 7 are a HOLD (4.67%), 15 are a SELL (10%).

Christopher Marai

Work Performance Price Targets & Ratings Chart

Analyst Christopher Marai, carries an average stock price target met ratio of 57.56% that have a potential upside of 65.5% achieved within 385 days. Previously, Christopher Marai worked at NOMURA, OPPENHEIMER.

Christopher Marai’s has documented 303 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRBP, Corbus Pharmaceuticals at 04-Jun-2020.

Wall Street Analyst Christopher Marai

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/20/2016. The price target of $60 was fulfilled within 94 days with a profit of $42.15 (236.13%) receiving and performance score of 25.12.

Average potential price target upside

of $86.94 (89.3%) on ARGX (ARGENX NV ADR).
of $51.99 (17.34%) on BIIB (BIOGEN).
of $34.87 (31.12%) on ALXN (ALEXION PHARMACEUTICALS).

ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals BIIB Biogen BMRN Biomarin Pharmaceutical INCY yte PTCT PTC Therapeutics SRPT Sarepta Therapeutics XNCR Xencor FPRX Five Prime Therapeutics QURE Uniqure NV CLLS Cellectis SA GBT Global Blood Therapeutics GLPG Galapagos NV ADR PRTA Prothena plc PTGX Protagonist Therapeutics SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals ARGX argenx NV ADR CRBP Corbus Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC IMGN ImmunoGen MGNX MacroGenics MITO Stealth BioTherapeutics Corp VYGR Voyager Therapeutics CTMX CytomX Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Keay Nakae (CHARDAN CAPITAL)